Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger FYVE domain-containing protein 19 (ZFYVE19) is a metal binding protein that plays a critical role in the regulation of the abscission step in cytokinesis, specifically as part of the NoCut checkpoint pathway, which delays cell separation to ensure proper chromosome segregation. The protein localizes primarily at the centrosome and binds phosphatidylinositol-3-phosphate, indicating involvement in lipid and protein interactions during cell division. Pathogenic mutations, particularly biallelic loss-of-function variants, in ZFYVE19 are linked to pediatric-onset cholestatic liver diseases, including congenital hepatic fibrosis, sclerosing cholangiopathy, and high-GGT cholestasis. There is currently no evidence supporting direct targeting of ZFYVE19 by therapeutic drugs, nor is it commonly used as a biomarker or therapeutic target in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger FYVE domain-containing protein 19 (ZFYVE19).